Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05731934 | The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT05905614 | Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 29 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Jun 17, 2024 |
| NCT06456216 | Performance Evaluation of Diagnostic Accuracy of PanTum Detect Test for Detection of Solid Tumours in Known Cancer Population and in Cancer Free Population. | completed | — | 90 | Max Healthcare Insititute LimitedOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03061188 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | completed | Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03617692 | Cannabis Use in Cancer Patients | completed | — | 27 | University of Colorado, DenverOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT04638491 | Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients | completed | Phase 1 | 32 | Luye Pharma Group Ltd.INDUSTRY | 1 | Jun 10, 2024 | clinicaltrials |
| NCT02834052 | Pembrolizumab + Poly-ICLC in MRP Colon Cancer | completed | Phase 1 / Phase 2 | 42 | Asha NayakOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT02318329 | Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors | completed | Phase 1 | 79 | Five Prime Therapeutics, Inc.INDUSTRY | 3 | Jun 4, 2024 | clinicaltrials |
| NCT04336098 | Study of SRF617 in Patients With Advanced Solid Tumors | completed | Phase 1 | 85 | Coherus Oncology, Inc.INDUSTRY | 2 | Jun 4, 2024 | clinicaltrials |
| NCT05054348 | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors | completed | Phase 1 | 91 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05309187 | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors | completed | Phase 1 | 22 | Immune-Onc TherapeuticsINDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT02834611 | Ceramide NanoLiposome in Patients With Advanced Solid Tumors | completed | Phase 1 | 14 | Keystone Nano, IncINDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT05036408 | Cancer Pain Rehabilitation Program to Reduce Pain Related Distress, and Reliance of Pain Medication Through Multimodal Nonpharmacological Solutions | completed | N/A | 16 | City of Hope Medical CenterOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04400383 | Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors | completed | Phase 1 | 62 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT05508100 | Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors | completed | Phase 1 | 38 | Immune-Onc TherapeuticsINDUSTRY | 1 | May 24, 2024 | clinicaltrials |
| NCT03238027 | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors | completed | Phase 1 | 45 | Syndax PharmaceuticalsINDUSTRY | 1 | May 17, 2024 | clinicaltrials |
| NCT02640508 | Eribulin and Lenvatinib in Advanced Solid Tumors | completed | Phase 2 | 29 | Virginia G. KaklamaniOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT01851369 | TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | May 8, 2024 | clinicaltrials |
| NCT04887194 | PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates | completed | Phase 1 | 40 | Mirati Therapeutics Inc.INDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT02261285 | ONO-4538 Phase I Study in Patients With Solid Tumor | completed | Phase 1 | 18 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 6, 2024 | clinicaltrials |
| NCT02261298 | ONO-4538 Phase I Study in Patients With Solid Tumor | completed | Phase 1 | 18 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT02517398 | MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors | completed | Phase 1 | 600 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 12 | May 3, 2024 | clinicaltrials |
| NCT04403308 | ONO-7913 Phase I Study (ONO-7913) | completed | Phase 1 | 7 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05054998 | Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases | completed | Phase 4 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT03874897 | Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors. | completed | Phase 1 | 134 | Peking UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT01447732 | Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 71 | Kyowa Kirin Co., Ltd.INDUSTRY | 0 | Apr 29, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT00921336 | Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor | completed | Phase 1 | 13 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT00940225 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | completed | Phase 2 | 730 | ExelixisINDUSTRY | 5 | Apr 25, 2024 | clinicaltrials |
| NCT02301130 | Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors | completed | Phase 1 | 64 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02705105 | Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 114 | Kyowa Kirin, Inc.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT02867007 | KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 36 | Kyowa Kirin, Inc.INDUSTRY | 2 | Apr 25, 2024 | clinicaltrials |
| NCT05173792 | Study of AK119 in Subjects With Advanced Solid Tumors | completed | Phase 1 | 16 | AkesoINDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05108623 | A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors | completed | Phase 1 | 34 | MiNK TherapeuticsINDUSTRY | 1 | Apr 24, 2024 | clinicaltrials |
| NCT04402606 | Study on Skin Toxicities Induced by Cancer Treatments(DERMACLIC) | completed | N/A | 292 | Institut CurieOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03969082 | Evaluation of Bibliotherapy by Students and Patients With Cancer | completed | N/A | 40 | University Hospital, GhentOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT04059588 | A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin | completed | Phase 1 | 16 | Rockefeller UniversityOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05001516 | Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid Tumors | completed | Phase 1 | 17 | Turning Point Therapeutics, Inc.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06372223 | A Food Effect Study of SPH5030 Tablets. | completed | Phase 1 | 16 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02054741 | Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer | completed | N/A | 733 | Supriya MohileOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02107443 | Improving Communication in Older Cancer Patients and Their Caregivers(COACH) | completed | N/A | 546 | Supriya MohileOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05160051 | 68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer | completed | Phase 2 | 158 | University Hospital, EssenOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT03861156 | D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer | completed | Phase 2 | 290 | InventisBio Co., LtdINDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04557306 | Evaluationn of Tolerability and Safety of CBT101, an Autologous Natural Killer Cell, in Patients With Solid Cancer | completed | Phase 1 | 6 | CHABiotech CO., LtdINDUSTRY | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03206021 | COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors(COZMOS) | completed | Phase 1 | 31 | The Hospital for Sick ChildrenOTHER | 3 | Apr 5, 2024 | clinicaltrials |
| NCT03490669 | Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors | completed | Phase 1 | 41 | AstraZenecaINDUSTRY | 3 | Apr 5, 2024 | clinicaltrials |
| NCT05950399 | Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk | completed | N/A | 52 | Mayo ClinicOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT03890731 | A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed | completed | Phase 2 | 6 | BayerINDUSTRY | 5 | Apr 2, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2024source: clinicaltrials